Cyprium Therapeutics, Inc.

Cyprium, a Fortress Biotech company, is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders.

Recent Press Releases

August 2020 :: Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

July 2020 :: Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

July 2020 :: Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports

June 2020 :: Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports

January 2020 :: Fortress Biotech Announces Rare Pediatric Disease Designation For CUTX-101 For The Treatment of Menkes Disease